LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Geron Corporation (“Geron” or the “Company) (NASDAQ: GERN) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Geron investigation page on our website www.glancylaw.com/case/geron-corporation.
On March 27, 2018, STAT published a report revealing that the Company’s recent stock performance was due to "flimsy" claims in connection to the efficacy of imetelstat, Geron's experimental myelofibrosis treatment. STAT stated that the available data for imetelstat undercuts Geron's representations as to the drug's efficacy. On this news, Geron's share price fell $0.83, or 13.88%, to close at $5.15 on March 27, 2018, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased Geron securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.